Adimmune
A Taiwan-based vaccine and biologics manufacturer offering end-to-end development and contract development and manufacturing (CDMO) services. Core operations include cell culture and egg-based vaccine production, aseptic fill-finish (vial and prefilled syringe), analytical and quality systems, regulatory support for global market entry, and environmental and occupational health management. The company holds multiple international GMP certifications and collaborates with academic and industry partners.
Industries
Nr. of Employees
large (251-1000)
Adimmune
No. 3, Sec. 1, Tanxing Rd., Tanzi Dist., Taichung City 427003, Taiwan (R.O.C.)
Patents
Products
Seasonal and pandemic influenza vaccines
Production and supply of trivalent and quadrivalent seasonal influenza vaccines and pandemic influenza vaccine readiness under pandemic preparedness agreements.
Tetanus toxoid and other routine vaccines
Manufacture of tetanus toxoid vaccine and other routine immunizations such as Japanese encephalitis and enterovirus vaccines.
Seasonal and pandemic influenza vaccines
Production and supply of trivalent and quadrivalent seasonal influenza vaccines and pandemic influenza vaccine readiness under pandemic preparedness agreements.
Tetanus toxoid and other routine vaccines
Manufacture of tetanus toxoid vaccine and other routine immunizations such as Japanese encephalitis and enterovirus vaccines.
Services
End-to-end CDMO services including process development, scale-up, GMP manufacturing, fill–finish, quality control, and regulatory support.
Analytical method development, method validation support, qualification testing, sterility testing, and stability programs for biologics.
Regulatory operations, CMC development, quality and compliance documentation, and dialogue with global regulatory authorities to support marketing authorization.
Process optimization, scale-up assistance from laboratory to commercial bioreactors, and implementation of QbD principles.
End-to-end CDMO services including process development, scale-up, GMP manufacturing, fill–finish, quality control, and regulatory support.
Analytical method development, method validation support, qualification testing, sterility testing, and stability programs for biologics.
Regulatory operations, CMC development, quality and compliance documentation, and dialogue with global regulatory authorities to support marketing authorization.
Process optimization, scale-up assistance from laboratory to commercial bioreactors, and implementation of QbD principles.
Expertise Areas
- CDMO services for vaccines and biologics
- Vaccine R&D and clinical trial support
- Cell culture and egg-based vaccine manufacturing
- Aseptic fill–finish and packaging
Key Technologies
- Cell culture production
- Embryo egg-based production
- Single-use bioreactors
- Aseptic isolator operations
News & Updates
Manufacturing plant received GMP certification from Brazil's ANVISA following on-site inspection, advancing regulatory approval in Brazil.
Urgent delivery of 5,000 doses of tetanus vaccine to a disaster-affected area in coordination with local public health authorities to protect residents and relief workers.
Implementation of QbD practices across process design and product development to strengthen process control and support international CDMO projects.
Execution of a Standard Material Transfer Agreement enabling access to influenza virus strains for pandemic response and committing supply portions for global pandemic needs.
Manufacturing lines have received GMP certifications from regulators including EMA, US FDA, Health Canada, TFDA, and ANVISA.
Achievement of ISO 14001 certification for environmental management in 2023.
Manufacturing plant received GMP certification from Brazil's ANVISA following on-site inspection, advancing regulatory approval in Brazil.
Urgent delivery of 5,000 doses of tetanus vaccine to a disaster-affected area in coordination with local public health authorities to protect residents and relief workers.
Implementation of QbD practices across process design and product development to strengthen process control and support international CDMO projects.
Execution of a Standard Material Transfer Agreement enabling access to influenza virus strains for pandemic response and committing supply portions for global pandemic needs.
Manufacturing lines have received GMP certifications from regulators including EMA, US FDA, Health Canada, TFDA, and ANVISA.
Achievement of ISO 14001 certification for environmental management in 2023.